News

AIFA. Public consultation on the list of drugs dangerous for driving

Public consultation on the list of dangerous drugs for driving pursuant to art. 55 of law 120/2010

The Italian Medicines Agency (AIFA) has decided to open a public consultation, pursuant to law 241/90 and subsequent amendments, on the attached document, containing the list of dangerous drugs for driving and classified according to the criteria established by the integrated project of the European Commission DRUID (Driving under the Influence of Drugs, Alcohol and Medicines) (attachment 1). This document will be incorporated as a technical attachment to a Ministerial Decree to be issued by the Ministry of Health. The explanation of the risk categories is given in attachment 2.

With this consultation initiative, AIFA intends to collect the comments and proposals of the owners AIC in order to draw up a list as exhaustive and updated as possible of the principles Risultati immagini per colpo di sonno in autoactive ingredients that may affect the ability to drive and operate machinery.

All holders of medicinal products that contain warnings on the ability to drive and operate machinery in the printouts, and which are not included in the attached list, are invited to notify them to the following email address farmacovigilanza@aifa.gov.it, together with a classification proposal using the same format as the attached list.

Likewise, proposals for justified modifications of the classification of substances already included in the attached list may be sent, always to the same email address, using the same format.

The public consultation will end on the ninetieth day from the date of publication on the AIFA web portal.

AIFA. Notice to Companies – 23/01/2017

 

 

 

Redazione Fedaiisf

Promote the cohesion and union of all members to allow a univocal and homogeneous vision of the professional problems inherent in the activity of pharmaceutical sales reps.

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco